Morningstar Investor users sign in here.

Company Profile

  • Business description

    Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.

  • Contact

    1185 Avenue of the Americas
    3rd Floor
    New York NY 10036

    T: +1 973 242-0005

  • Sector


    Stock type


  • Industry


    Fiscal Year End

    31 December 2024



Stocks News & Analysis


Market is underestimating ASX pathology shares

Morningstar sees several reasons to expect a stronger recover than market consensus.

What is next for BHP and Anglo

As the deadline for raising the bid approaches we lower our fair value estimate for BHP.

4 cheap ASX shares owned by top-rated funds

These companies could offer good value and have the stamp of approval from Morningstar Gold Medalist equity funds.

Market Movers

Last price
% Change
Jupiter Mines Ltd JMS 0.32 0.04 -9.86%
Sayona Mining Ltd SYA 0.04 0.01 -12.24%
Telstra Group Ltd TLS 3.57 0.10 -2.72%
The Star Entertainment Group Ltd SGR 0.50 0.04 -7.41%
South32 Ltd S32 3.90 0.01 0.26%
Imugene Ltd IMU 0.07 0.00 0.00%
Alligator Energy Ltd AGE 0.07 0.00 3.08%
Pilbara Minerals Ltd PLS 4.15 0.05 -1.19%
Red 5 Ltd RED 0.49 0.02 3.16%
Peninsula Energy Ltd PEN 0.12 0.01 -4.17%